Relay Therapeutics (RLAY) Other Gross PP&E Adjustments (2019 - 2026)
Relay Therapeutics (RLAY) reported Other Gross PP&E Adjustments of -$38.6 million for Q1 2026, up 23.02% year-over-year from -$31.4 million in Q1 2025, and down 19.2% on a QoQ basis from -$32.4 million in Q4 2025.
Relay Therapeutics (RLAY) has 8 years of Other Gross PP&E Adjustments data on file, last reported at -$38.6 million in Q1 2026.
- Quarterly Other Gross PP&E Adjustments rose 23.02% year-over-year to -$38.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$38.6 million (up 23.02% YoY) and the FY2025 annual result came in at -$32.4 million, up 4.3% from the prior year.
- Other Gross PP&E Adjustments slipped to -$38.6 million in Q1 2026 per RLAY's latest filing, from -$32.4 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$19.8 million in Q2 2022 and bottomed at -$65.2 million in Q3 2022.
- The 5-year median for Other Gross PP&E Adjustments is -$48.2 million (2022), against an average of -$46.3 million.
- The widest annual swing landed in 2022, when Other Gross PP&E Adjustments plunged 485.16%; it then gained 23.02% in 2026.
- Tracing RLAY's Other Gross PP&E Adjustments over 5 years: stood at -$48.2 million in 2022, then increased by 11.0% to -$42.9 million in 2023, then grew by 21.2% to -$33.8 million in 2024, then grew by 4.3% to -$32.4 million in 2025, then decreased by 19.2% to -$38.6 million in 2026.
- Per Business Quant, the three latest RLAY Other Gross PP&E Adjustments figures stand at -$38.6 million (Q1 2026), -$32.4 million (Q4 2025), and -$42.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Relay Therapeutics | 2.53 Bn | 2.53 Bn | - | -38.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.59 Mn |
| Mar 31, 2026 | -38.59 Mn |
| Dec 31, 2025 | -32.38 Mn |
| Dec 31, 2025 | -32.38 Mn |
| Sep 30, 2025 | -42.24 Mn |
| Sep 30, 2025 | -42.24 Mn |
| Jun 30, 2025 | -46.23 Mn |
| Jun 30, 2025 | -46.23 Mn |
| Mar 31, 2025 | -50.14 Mn |
| Mar 31, 2025 | -50.14 Mn |
| Dec 31, 2024 | -33.83 Mn |
| Dec 31, 2024 | -33.83 Mn |
| Sep 30, 2024 | -53.36 Mn |
| Sep 30, 2024 | -53.36 Mn |
| Jun 30, 2024 | -54.92 Mn |
| Jun 30, 2024 | -54.92 Mn |
| Mar 31, 2024 | -56.46 Mn |
| Mar 31, 2024 | -56.46 Mn |
| Dec 31, 2023 | -42.93 Mn |
| Dec 31, 2023 | -42.93 Mn |
| Sep 30, 2023 | -59.45 Mn |
| Sep 30, 2023 | -59.45 Mn |
| Jun 30, 2023 | -60.91 Mn |
| Jun 30, 2023 | -60.91 Mn |
| Mar 31, 2023 | -62.34 Mn |
| Mar 31, 2023 | -62.34 Mn |
| Dec 31, 2022 | -48.24 Mn |
| Dec 31, 2022 | -48.24 Mn |
| Sep 30, 2022 | -65.15 Mn |
| Sep 30, 2022 | -65.15 Mn |
| Jun 30, 2022 | -19.83 Mn |
| Jun 30, 2022 | -19.83 Mn |
| Mar 31, 2022 | -20.31 Mn |
| Mar 31, 2022 | -20.31 Mn |
| Dec 31, 2021 | -8.24 Mn |
| Dec 31, 2021 | -8.24 Mn |
| Jun 30, 2021 | -21.69 Mn |
| Jun 30, 2021 | -21.69 Mn |
| Mar 31, 2021 | -22.13 Mn |
| Mar 31, 2021 | -22.13 Mn |
| Dec 31, 2020 | -10.30 Mn |
| Dec 31, 2020 | -10.30 Mn |
| Sep 30, 2020 | -22.37 Mn |
| Sep 30, 2020 | -22.37 Mn |
| Jun 30, 2020 | -22.78 Mn |
| Jun 30, 2020 | -22.78 Mn |
| Dec 31, 2019 | -9.02 Mn |
| Dec 31, 2019 | -9.02 Mn |